Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Shares Outstanding (2016 - 2025)

Cytosorbents (CTSO) has disclosed Shares Outstanding for 14 consecutive years, with $62.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding rose 15.22% year-over-year to $62.8 million, compared with a TTM value of $62.8 million through Sep 2025, up 15.22%, and an annual FY2024 reading of $54.8 million, up 1.09% over the prior year.
  • Shares Outstanding was $62.8 million for Q3 2025 at Cytosorbents, roughly flat from $62.6 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $62.8 million in Q3 2025 and bottomed at $43.3 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $49.5 million, with a median of $44.2 million recorded in 2023.
  • The sharpest move saw Shares Outstanding increased 0.36% in 2022, then rose 24.3% in 2023.
  • Year by year, Shares Outstanding stood at $43.5 million in 2021, then grew by 0.36% to $43.6 million in 2022, then rose by 24.3% to $54.2 million in 2023, then grew by 1.09% to $54.8 million in 2024, then rose by 14.53% to $62.8 million in 2025.
  • Business Quant data shows Shares Outstanding for CTSO at $62.8 million in Q3 2025, $62.6 million in Q2 2025, and $62.5 million in Q1 2025.